Insuffisance érectile : Prescrire un inhibiteur de la phosphodiestérase 5 en première intentionSTAERMAN, Frédéric.Concours médical (Paris). 2009, Vol 131, Num 7, pp 221-224, issn 0010-5309, 4 p.Article

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risksJACKSON, G; ARVER, S; BANKS, I et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 4, pp 497-504, issn 1368-5031, 8 p.Article

Isolation and identification of thiohomosildenafil and thiosildenafil in health supplementsPENG ZOU; PEILING HOU; OH, Sharon Sze-Yin et al.Journal of pharmaceutical and biomedical analysis. 2008, Vol 47, Num 2, pp 279-284, issn 0731-7085, 6 p.Article

Safety of Prescribing PDE-5 Inhibitors via e-Medicine vs Traditional MedicineMUNGER, Mark A; STODDARD, Gregory J; WENNER, Allen R et al.Mayo Clinic proceedings. 2008, Vol 83, Num 8, pp 890-896, issn 0025-6196, 7 p.Article

Phosphodiesterase Type 5 Inhibitor Use and Hearing ImpairmentMCGWIN, Gerald.Archives of otolaryngology, head & neck surgery. 2010, Vol 136, Num 5, pp 488-492, issn 0886-4470, 5 p.Article

Hemodynamic and exercise effects of phosphodiesterase 5 inhibitorsJACKSON, Graham.The American journal of cardiology. 2005, Vol 96, Num 12B, pp 32M-36M, issn 0002-9149Conference Paper

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitorsDRESSER, M. J; DESAI, D; GIDWANI, S et al.International journal of impotence research. 2006, Vol 18, Num 1, pp 104-110, issn 0955-9930, 7 p.Article

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors : Focus on «-blocker interactionsKLONER, Robert A.The American journal of cardiology. 2005, Vol 96, Num 12B, pp 42M-46M, issn 0002-9149Conference Paper

Isolation and structure elucidation of an interaction product of aminotadalafil found in an illegal health food productHÄBERLI, Adrian; GIRARD, Philippe; LOW, Min-Yong et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 53, Num 1, pp 24-28, issn 0731-7085, 5 p.Article

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial HypertensionARCHER, Stephen L; MICHELAKIS, Evangelos D.The New England journal of medicine. 2009, Vol 361, Num 19, pp 1864-1871, issn 0028-4793, 8 p.Article

Classification trees based on infrared spectroscopic data to discriminate between genuine and counterfeit medicinesDECONINCK, E; SACRE, P. Y; COOMANS, D et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 57, Num C, pp 68-75, issn 0731-7085, 8 p.Article

The Successful Use of Phosphodiesterase Type 5 Inhibitors to Treat the Syndrome of Cor Pulmonale and Prerenal Azotemia with Diuresis of Anasarca (CorPRADA)BEREZ, Paul Bruce.Southern medical journal (Birmingham, Ala. Print). 2010, Vol 103, Num 2, pp 116-120, issn 0038-4348, 5 p.Article

Effect of phosphodiesterase-5 inhibitor on hearingOKUYUCU, S; GUVEN, O. E; AKOGLU, E et al.Journal of laryngology and otology. 2009, Vol 123, Num 7, pp 718-722, issn 0022-2151, 5 p.Article

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysisTSERTSVADZE, Alexander; FINK, Howard A; FOX, Steven et al.Annals of internal medicine. 2009, Vol 151, Num 9, pp 650-661, issn 0003-4819, 12 p.Article

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunctionSADOVSKY, R; BROCK, G. B; GUTKIN, S. W et al.International journal of clinical practice (Esher). 2009, Vol 63, Num 8, pp 1214-1230, issn 1368-5031, 17 p.Article

Phosphodiesterase 5 inhibitors : Drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles : Phosphodiesterase 5 inhibitors : pharmacology and therapeutic perspectivesSUPURAN, Claudiu T; MASTROLORENZO, Antonio; BARBARO, Giuseppe et al.Current pharmaceutical design. 2006, Vol 12, Num 27, pp 3459-3465, issn 1381-6128, 7 p.Article

Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expressionTSAI, Ben M; TURRENTINE, Mark W; SHERIDAN, Brett C et al.The Annals of thoracic surgery. 2006, Vol 81, Num 1, pp 272-278, issn 0003-4975, 7 p.Conference Paper

Lifestyle and metabolic approaches to maximizing erectile and vascular healthMELDRUM, D. R; GAMBONE, J. C; MORRIS, M. A et al.International journal of impotence research. 2012, Vol 24, Num 2, pp 61-68, issn 0955-9930, 8 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article

Phosphodiesterase-5 inhibitors and rosacea : report of 10 casesIOANNIDES, D; LAZARIDOU, E; APALLA, Z et al.British journal of dermatology (1951). 2009, Vol 160, Num 3, pp 719-720, issn 0007-0963, 2 p.Article

How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitorGOOREN, Louis.Journal of men's health. 2008, Vol 5, Num 2, pp 163-170, 8 p.Article

Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplementXIAOWEI GE; LOW, Min-Yong; PENG ZOU et al.Journal of pharmaceutical and biomedical analysis. 2008, Vol 48, Num 4, pp 1070-1075, issn 0731-7085, 6 p.Article

Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lambJAILLARD, Sophie; LARRUE, Benoit; DERUELLE, Philippe et al.The Annals of thoracic surgery. 2006, Vol 81, Num 3, pp 935-942, issn 0003-4975, 8 p.Article